Odense University Hospital registers OPTICARE cardiorenal clinic trial for CKD and heart disease
A new trial from Odense University Hospital will test whether a specialised Cardio-Renal Clinic improves outcomes for patients with chronic kidney disease and cardiovascular disease.
This week's update covers one newly registered trial sponsored by Odense University Hospital.
- "Optimised Multidisciplinary Cardiovascular and Renal Protection in Patients With Chronic Kidney Disease and Cardiovascular Disease" (NCT07835828, OPTICARE) is not yet recruiting, with an estimated start of October 1, 2026. The study is a randomized, controlled, open-label, parallel-group trial run at a single center, enrolling 500 participants who have both cardiovascular disease and chronic kidney disease.1 It will compare care in a specialized clinic against usual care, testing whether it improves measures of heart and kidney function, quality of life, symptoms, and physical ability after one year, and whether it reduces the risk of death, hospitalization for heart failure, heart attack, stroke, worsening kidney function, or kidney failure after five years.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.